idarubicin has been researched along with cyclosporine in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (40.74) | 18.2507 |
| 2000's | 12 (44.44) | 29.6817 |
| 2010's | 4 (14.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Clardy, J; Derbyshire, ER; Mota, MM; Prudêncio, M | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cornblatt, B; Doyle, LA; Ross, DD; Tong, Y; Yang, W | 1 |
| Baccarani, M; Baraldo, M; Damiani, D; Fanin, R; Furlanut, M; Michelutti, A; Michieli, M; Pea, F; Russo, D | 1 |
| al-Sabah, A; Baines, P; Burnett, A; Hoy, T; Limaye, M; Padua, RA; Whittaker, J | 1 |
| Estey, EH; Simon, RM; Thall, PF | 1 |
| Abbadessa, V; Cajozzo, A; Gancitano, RA; Musso, M; Perricone, R; Porretto, F; Tolomeo, M | 1 |
| Borg, AG; Burgess, R; Fisher, A; Grey, M; Wood, P; Yin, JA | 1 |
| Garnier-Suillerot, A; Mankhetkorn, S | 1 |
| Baccarani, M; Baraldo, M; Damiani, D; Ermacora, A; Fanin, R; Furlanut, M; Michieli, M; Pea, F; Russo, D; Zaja, F | 1 |
| Barbui, T; Bassan, R; Chiodini, B | 1 |
| Baccarani, M; Baraldo, M; Damiani, D; Ermacora, A; Fanin, R; Furlanut, M; Michieli, M; Pea, F; Russo, D | 1 |
| Ağaoğlu, L; Anak, S; Erdem, S; Gedikoğlu, G; Hacibektaşoğlu, A; Karakaş, Z | 1 |
| de Witte, T; Linssen, P; Masereeuw, R; Muus, P; Raymakers, R; Smeets, M; Vierwinden, G | 1 |
| Arcese, W; Cerretti, R; De Felice, L; Donato, V; Fenu, S; Guglielmi, C; Iori, A; Laurenti, L; Mengarelli, A; Micozzi, A; Romano, A; Torromeo, C | 1 |
| Barbui, T; Bassan, R; Borleri, G; Buelli, M; Chiodini, B; Lerede, T; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Döhner, H; Gabler, A; Haas, R; Hartmann, F; Hensel, M; Ho, AD; Jung, W; Schlenk, RF; Trümper, L; Weber-Nordt, R | 1 |
| Abe, Y; Choi, I; Inaba, S; Matsushima, T; Muta, K; Nagasawa, E; Nawata, H; Nishimura, J; Ohtsuka, R; Tachikawa, Y | 1 |
| Apostolidis, I; Arvanitopoulou, E; Asprogeraka, T; Bakiri, M; Giannakoulas, N; Kotsianidis, I; Marinakis, T; Matsouka, P; Pagoni, M; Papaioannou, M; Skandali, A; Spanoudakis, E; Tsatalas, K; Viniou, N; Yataganas, X; Zikos, P | 1 |
| Chen, SG; Li, GY; Liu, JZ; Wang, CB; Wang, LX; Zhang, B | 1 |
| Gellert, P; Le, H; Schatzlein, A; Siew, A; Thiovolet, M; Uchegbu, I | 1 |
| Tohyama, K | 1 |
2 review(s) available for idarubicin and cyclosporine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
5 trial(s) available for idarubicin and cyclosporine
| Article | Year |
|---|---|
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Chemotherapy, Adjuvant; Creatinine; Cyclosporine; Cytarabine; Feasibility Studies; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Treatment Outcome | 1998 |
Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Male; Maximum Tolerated Dose; Middle Aged; Salvage Therapy; Treatment Outcome | 2002 |
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Data Interpretation, Statistical; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Greece; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Remission Induction; Societies, Medical; Survival Analysis; Treatment Outcome | 2006 |
Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Cyclosporine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorescent Dyes; Humans; Idarubicin; Inhibitory Concentration 50; K562 Cells; Leukemia, Myeloid, Acute; Male; Rhodamine 123; Time Factors; Treatment Outcome; Verapamil | 2009 |
20 other study(ies) available for idarubicin and cyclosporine
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
Topics: Animals; Anopheles; Antimalarials; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Inhibitory Concentration 50; Insect Vectors; Life Cycle Stages; Liver; Malaria; Malaria, Falciparum; Male; Mice; Mice, Inbred C57BL; Plasmodium berghei; Plasmodium falciparum; Treatment Outcome | 2012 |
Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Breast Neoplasms; Cell Survival; Culture Media; Cyclosporine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Stability; HL-60 Cells; Humans; Idarubicin; Intracellular Fluid; Tumor Cells, Cultured | 1995 |
P170-related multidrug resistance. Enhancement of idarubicin content in leukemic cells with cyclosporin in vivo: a report of two cases.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Drug Resistance, Multiple; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged | 1995 |
In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Bone Marrow; Bone Marrow Cells; Cell Survival; Cells, Cultured; Cyclosporine; Daunorubicin; Drug Resistance; Drug Resistance, Multiple; Female; Fluorescent Antibody Technique; Humans; Idarubicin; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Monocytes; Reference Values | 1994 |
New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; Cyclosporine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mathematical Computing; Monitoring, Physiologic; Probability; Remission Induction; Research Design | 1996 |
Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Daunorubicin; Drug Resistance, Multiple; Flow Cytometry; Idarubicin; Immunosuppressive Agents; Tumor Cells, Cultured | 1996 |
Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Coloring Agents; Cyclosporine; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1997 |
The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Daunorubicin; Doxorubicin; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; Idarubicin; Leukemia; Tumor Cells, Cultured; Verapamil | 1998 |
Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Cyclosporine; Daunorubicin; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Idarubicin; Immunosuppressive Agents; Leukemia; Tumor Cells, Cultured | 1999 |
Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia.
Topics: Cyclosporine; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Idarubicin; Leukemia, Myeloid, Acute; Time Factors; Verapamil | 1999 |
MTT assay for drug resistance in childhood acute leukemia and effect of cyclosporin and interferon. A preliminary report.
Topics: Antineoplastic Agents; Bone Marrow; Cell Survival; Child; Cyclosporine; Drug Screening Assays, Antitumor; Humans; Idarubicin; Interferon alpha-2; Interferon-alpha; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Recombinant Proteins; Tumor Cells, Cultured | 1999 |
Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Daunorubicin; Female; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Prospective Studies; Recurrence | 2001 |
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Infant; Leukemia; Life Tables; Male; Methylprednisolone; Middle Aged; Premedication; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2002 |
Successful treatment with nonmyeloablative allogeneic hematopoietic stem cell transplantation in a patient with acute myeloid leukemia complicated with pulmonary infection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Combined Modality Therapy; Cyclosporine; Cytarabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pneumonia; Prednisone; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles.
Topics: Adhesiveness; Animals; Anti-Ulcer Agents; Antibiotics, Antineoplastic; Antifungal Agents; Caco-2 Cells; Chitosan; Cyclosporine; Drug Carriers; Griseofulvin; Humans; Hydrophobic and Hydrophilic Interactions; Idarubicin; Intestinal Absorption; Intestinal Mucosa; Intestine, Small; Male; Nanoparticles; Quaternary Ammonium Compounds; Ranitidine; Rats; Rats, Wistar | 2012 |